Search Results for: netter 1

Efficacy and safety of 177 Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study

https://www.adacap.com/de/publications/efficacy-and-safety-of-177-lu%e2%80%91dotatate-in-patients-with-advanced-pancreatic-neuroendocrine-tumours-data-from-the-netter-r-international-retrospective-study/

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

https://www.adacap.com/de/publications/%c2%b9%e2%81%b7%e2%81%b7lu-dotatate-plus-long-acting-octreotide-versus-high%e2%80%91dose-long-acting-octreotide-in-patients-with-midgut-neuroendocrine-tumours-netter-1-final-overall-survival-and-lo/

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

https://www.adacap.com/de/novartis-reports-clinically-relevant-improvement-in-median-overall-survival-data-in-final-analysis-of-pivotal-netter-1-study-with-targeted-radioligand-therapy-lutathera/

Netter-1

https://www.adacap.com/de/clinical_trials/netter-1/

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-DOTATATE: an analysis of the NETTER-1 study

https://www.adacap.com/de/publications/impact-of-liver-tumour-burden-alkaline-phosphatase-elevation-and-target-lesion-size-on-treatment-outcomes-with-177lu-dotatate-an-analysis-of-the-netter-1-study/

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

https://www.adacap.com/de/novartis-announces-presentation-of-new-lutathera-netter-1-data-at-esmo-demonstrating-significant-improvement-in-pfs-regardless-of-baseline-liver-tumor-burden/

Novartis today announced presentation of a new analysis of Lutathera® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden....

Impact of Liver Tumor Burden on Therapeutic Effect of 177Lu-DOTATATE Treatment in NETTER-1

https://www.adacap.com/de/publications/impact-of-liver-tumor-burden-on-therapeutic-effect-of-177lu-dotatate-treatment-in-netter-1/

EANM 2018: NETTER-1 Study Abstracts

https://www.adacap.com/de/publications/eanm-2018-netter-1-study-abstracts/

Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors

https://www.adacap.com/de/publications/clinical-outcomes-in-patients-with-baseline-renal-dysfunction-in-the-netter-1-study-177lu-dotatate-lutathera-vs-high-dose-octreotide-in-progressive-midgut-neuroendocrine-tumors/

First Update on Overall Survival, Progression-free Survival, and Time-to-deterioration of Health-related Quality of Life from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors

https://www.adacap.com/de/publications/first-update-on-overall-survival-progression-free-survival-and-time-to-deterioration-of-health-related-quality-of-life-from-the-netter-1-study-177lu-dotatate-lutathera-vs-high-dose-octreoti/